1 March 2018, Bengaluru. Unitus Seed Fund, India’s leading impact venture fund investing in early-stage startups innovating for the masses, today announced an investment in Predible Health, an AI powered cancer radiology platform.
Predible Health is powering the future of cancer diagnosis through its AI-powered clinical applications for liver and lung cancers, that enable radiologists to interpret images with superior accuracy and faster speed. Its cutting-edge algorithms unlock deep, hidden insights that aid physicians to characterize diseases, plan and deliver personalized treatment.
“Unitus’ funding will enable Predible to scale the development of our cancer AI platform as well as invest in regulatory approvals for our existing products. Our clinical validation studies are displaying positive results; we are now working to bring our offerings into clinical practice,” said Suthirth Vaidya, Chief Executive Officer, Predible Health.
Predible Health – Providing Effective Diagnosis Solutions for Liver and Lung Cancer Patients
India is projected to have an alarming ~1.7 million cancer patients by 2020. However, with an inadequate radiologists serving a population of more than a billion, there is a severe shortage of trained radiologists. Further, due to lack of robust tools in India’s healthcare market, radiology images are interpreted subjectively, often leading to ineffective diagnosis and treatment.
Predible is applying AI to medical imaging, enabling quicker delivery of care with increased accuracy by building patient-centric, organ-specific cancer care workflows that empower clinicians to understand the disease comprehensively. The results will significantly aid radiologists and oncologists to plan personalised, thus effective treatments.
Predible currently has two flagship products; Predible Liver that assists surgeons with precise planning for Liver Transplant and Tumor Resections, through instant analysis and 3D visualization of liver lesions and hepatic structures. Being built completely on the cloud, the solution is easily accessible by hospitals across India with an internet connection, enabling them to carefully plan surgeries and decrease morbidity.
It’s second product is Predible Lung, that helps in interpretation of lung nodules from CT images, enabling quicker detection and improved assessment of malignancy. Given the increasing growth in screening programs globally together with the large number of unnecessary biopsies carried out, Predible Lung is intended to help improve care for screening patients through improved early diagnosis.
“Physicians today spend a large amount of time in carrying out complex analysis tasks that are required for cancer care. Given the severe shortage of expertise, there is a strong need to improve accuracy and efficiency. Our solutions, Predible Liver and Predible Lung, will empower physicians to uncover data-driven insights and provide high-quality, personalized cancer care,” said Abhijith Chunduru, Chief Technology Officer, Predible Health.
He further said, “Apart from commercial product development, we are also engaging with leading medical institutions to pursue research in advancing deep learning technology to solve high-impact problems in healthcare for developing countries such as India.”
On Track to Process 500+ Million Images to Provide Unmatched Clinical Accuracy
Since inception, Predible Health has processed over 2 million images to train its deep learning algorithms and bring them to up to clinical accuracy. By December 2020, the company is aiming to scale this to 500 million images to bring accuracy of their products to levels that can match humans in any scenario.
Predible Health currently has tie-ups with some of India’s most recognized healthcare entities – Tata Memorial Hospital (Mumbai), Mahajan Imaging (Delhi) and Narayana Health (Bangalore).
Predible is an outcome of the research work that won the Longitudinal Multiple Sclerosis Lesion Segmentation Challenge held at the IEEE-International Symposium on Biomedical Imaging 2015.
About Predible Health
Predible Health is a Bangalore based startup which builds artificial intelligence enabled cloud software for radiology. Their initial products on Liver Surgery and Lung Cancer are undergoing clinical trials and is expected to be available for commercial use later this year. The company was founded by Suthirth Vaidya (B.Tech, M.Tech from IIT Madras), Abhijith Chunduru (B.Tech, M.Tech from IIT Madras) and Deepak Mohan (PGDM IIM Ahmedabad, B.Tech IIT Madras) shortly after their research work at IIT Madras, in May 2016. More about Predible Health >
About Unitus Seed Fund
Unitus Seed Fund is the leading impact venture fund investing in startups innovating for the masses in India. Unitus Seed Fund invests in sectors including healthcare, education, and financial services. Founded in 2012, Unitus Seed Fund is managed by Capria Ventures which is part of the Unitus Group, a premier financial services group operating in India and other emerging markets since 2000. Unitus Seed Fund is based in Bangalore and Seattle and is a member of the Capria Network. More about Unitus Seed Fund >